Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
Adenocarcinoma of the endometrium (also known as endometrial cancer, or more broadly as uterine cancer or carcinoma of the uterine corpus) is the most common malignancy of the female genital tract in the United States. It is estimated that 65,950 new uterine cancer cases will have occurred in 2022, with 12,550 deaths resulting from the disease. Endometrial carcinoma includes pure endometrioid cancer and carcinomas with high-risk endometrial histology (including uterine serous carcinoma, clear cell carcinoma, carcinosarcoma [also known as malignant mixed Müllerian tumor], and undifferentiated/dedifferentiated carcinoma). Stromal or mesenchymal sarcomas are uncommon subtypes accounting for approximately 3% of all uterine cancers. This selection from the NCCN Guidelines for Uterine Neoplasms focuses on the diagnosis, staging, and management of pure endometrioid carcinoma. The complete version of the NCCN Guidelines for Uterine Neoplasms is available online at NCCN.org.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
---|---|
Enthalten in: |
Journal of the National Comprehensive Cancer Network : JNCCN - 21(2023), 2 vom: 15. Feb., Seite 181-209 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Abu-Rustum, Nadeem [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Completed 27.02.2023 Date Revised 02.03.2023 published: Print Citation Status MEDLINE |
---|
doi: |
10.6004/jnccn.2023.0006 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM352982861 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM352982861 | ||
003 | DE-627 | ||
005 | 20231226054947.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.6004/jnccn.2023.0006 |2 doi | |
028 | 5 | 2 | |a pubmed24n1176.xml |
035 | |a (DE-627)NLM352982861 | ||
035 | |a (NLM)36791750 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Abu-Rustum, Nadeem |e verfasserin |4 aut | |
245 | 1 | 0 | |a Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 27.02.2023 | ||
500 | |a Date Revised 02.03.2023 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Adenocarcinoma of the endometrium (also known as endometrial cancer, or more broadly as uterine cancer or carcinoma of the uterine corpus) is the most common malignancy of the female genital tract in the United States. It is estimated that 65,950 new uterine cancer cases will have occurred in 2022, with 12,550 deaths resulting from the disease. Endometrial carcinoma includes pure endometrioid cancer and carcinomas with high-risk endometrial histology (including uterine serous carcinoma, clear cell carcinoma, carcinosarcoma [also known as malignant mixed Müllerian tumor], and undifferentiated/dedifferentiated carcinoma). Stromal or mesenchymal sarcomas are uncommon subtypes accounting for approximately 3% of all uterine cancers. This selection from the NCCN Guidelines for Uterine Neoplasms focuses on the diagnosis, staging, and management of pure endometrioid carcinoma. The complete version of the NCCN Guidelines for Uterine Neoplasms is available online at NCCN.org | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Practice Guideline | |
700 | 1 | |a Yashar, Catheryn |e verfasserin |4 aut | |
700 | 1 | |a Arend, Rebecca |e verfasserin |4 aut | |
700 | 1 | |a Barber, Emma |e verfasserin |4 aut | |
700 | 1 | |a Bradley, Kristin |e verfasserin |4 aut | |
700 | 1 | |a Brooks, Rebecca |e verfasserin |4 aut | |
700 | 1 | |a Campos, Susana M |e verfasserin |4 aut | |
700 | 1 | |a Chino, Junzo |e verfasserin |4 aut | |
700 | 1 | |a Chon, Hye Sook |e verfasserin |4 aut | |
700 | 1 | |a Chu, Christina |e verfasserin |4 aut | |
700 | 1 | |a Crispens, Marta Ann |e verfasserin |4 aut | |
700 | 1 | |a Damast, Shari |e verfasserin |4 aut | |
700 | 1 | |a Fisher, Christine M |e verfasserin |4 aut | |
700 | 1 | |a Frederick, Peter |e verfasserin |4 aut | |
700 | 1 | |a Gaffney, David K |e verfasserin |4 aut | |
700 | 1 | |a Giuntoli, Robert |e verfasserin |4 aut | |
700 | 1 | |a Han, Ernest |e verfasserin |4 aut | |
700 | 1 | |a Holmes, Jordan |e verfasserin |4 aut | |
700 | 1 | |a Howitt, Brooke E |e verfasserin |4 aut | |
700 | 1 | |a Lea, Jayanthi |e verfasserin |4 aut | |
700 | 1 | |a Mariani, Andrea |e verfasserin |4 aut | |
700 | 1 | |a Mutch, David |e verfasserin |4 aut | |
700 | 1 | |a Nagel, Christa |e verfasserin |4 aut | |
700 | 1 | |a Nekhlyudov, Larissa |e verfasserin |4 aut | |
700 | 1 | |a Podoll, Mirna |e verfasserin |4 aut | |
700 | 1 | |a Salani, Ritu |e verfasserin |4 aut | |
700 | 1 | |a Schorge, John |e verfasserin |4 aut | |
700 | 1 | |a Siedel, Jean |e verfasserin |4 aut | |
700 | 1 | |a Sisodia, Rachel |e verfasserin |4 aut | |
700 | 1 | |a Soliman, Pamela |e verfasserin |4 aut | |
700 | 1 | |a Ueda, Stefanie |e verfasserin |4 aut | |
700 | 1 | |a Urban, Renata |e verfasserin |4 aut | |
700 | 1 | |a Wethington, Stephanie L |e verfasserin |4 aut | |
700 | 1 | |a Wyse, Emily |e verfasserin |4 aut | |
700 | 1 | |a Zanotti, Kristine |e verfasserin |4 aut | |
700 | 1 | |a McMillian, Nicole R |e verfasserin |4 aut | |
700 | 1 | |a Aggarwal, Shaili |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of the National Comprehensive Cancer Network : JNCCN |d 2003 |g 21(2023), 2 vom: 15. Feb., Seite 181-209 |w (DE-627)NLM156397676 |x 1540-1413 |7 nnns |
773 | 1 | 8 | |g volume:21 |g year:2023 |g number:2 |g day:15 |g month:02 |g pages:181-209 |
856 | 4 | 0 | |u http://dx.doi.org/10.6004/jnccn.2023.0006 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 21 |j 2023 |e 2 |b 15 |c 02 |h 181-209 |